Canine Lyme Disease: What You Need to Know | Boehringer Ingelheim US Canine Lyme Disease: What You Need to Know | Boehringer Ingelheim US Click here to discover all you need to know about lyme disease in dogs; causes, symptoms, prevention, detection and treatment.
Protocols to Trim Mastitis in your Herd | Boehringer Ingelheim US Protocols to Trim Mastitis in your Herd | Boehringer Ingelheim US Read more on how the Boehringer Ingelheim mastitis grading chart protocols lead to creating better informed mastitis treatment decisions in livestock.
Telemedicine – the standalone study that became the new normal Telemedicine – the standalone study that became the new normal Dr Vijay Prabhakar tells us how a remote healing project made him a pandemic pioneer.Read it now!
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia
The power of patient advocacy in cancer care The power of patient advocacy in cancer care Patients and advocacy organizations agree that patient empowerment is key to quality cancer care
STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.
Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases
U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes
Boehringer inhalers now available at $35 a month for eligible patients Boehringer inhalers now available at $35 a month for eligible patients Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients